– Abstract on data from a two-part phase 1c, multiple ascending dose study accepted for oral presentation – – New data highlighting the Company’s lead drug candidate ZT002 for obesity – BEIJING, Sept. 3, 2024 /PRNewswire/ — Beijing QL Biopharmaceutical Co., Ltd. (“QL Biopharm”), a…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.